Company
Melbourne, VIC
Every investor coverage indicates participated in a round ENA Therapeutics raised.
Companies ENA Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming ENA Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Australian biotech ENA Respiratory raised funding led by Brandon Capital and Minderoo Foundation to advance its Covid-19 nasal spray toward the clinic, and appointed Ruth Tal-Singer to its board.
Ferret research found Ena Respiratory's INNA-051 nasal spray sharply lowered coronavirus levels; the biotech has banked an $11.7 million Series A and aims to begin human trials within months.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio